Kirkland, Wash. - Radiant Research Inc., a national clinical trials management company, announced today that it has acquired the Denver and Boca Raton investigative sites of Novoquest Research, Inc., a wholly owned subsidiary of Canadian Medical Laboratories Limited (TSE: CLC). The acquisition strengthens Radiant's expertise in conducting clinical trials for conditions affecting the central nervous system (CNS). Together, the Denver and Boca Raton sites have experience conducting more than 100 studies in a variety of areas including Alzheimer's disease, depression, attention deficit hyperactivity disorder (ADHD) and smoking cessation.

"I was particularly impressed with Radiant's centralized participant recruitment services and coordinator and investigator training programs," noted Leslie Moldauer, MD, medical director of the Denver site. "Now I have access to the knowledge-base of a company with thousands of studies under its belt."

Radiant owns more investigative sites than any organization in the country, allowing them to facilitate the development of new drugs, medical devices, and to conduct clinical trials more quickly and cost-effectively. With the addition of these experienced investigative sites to its network Radiant will be able to offer its biopharmaceutical clients the ability to more quickly initiate qualified CNS sites.

"We had identified CNS as an area where we wanted to increase our depth of expertise, and the two Novoquest sites were the best fit," commented Mike Lester, Radiant's chief executive officer and president. "We are honored to add to our team such experienced investigators as Drs. Eugene Du Boff and Leslie Moldauer in Denver, and Drs. Peter Holland and Donna Holland in Boca Raton."

                                                             ###

About Radiant Research
Based near Seattle, Washington, Radiant Research (radiantresearch.com) is a comprehensive clinical research and development company serving the biopharmaceutical and medical device industry. Radiant is comprised of more than 30 wholly-owned premier clinical research centers nationwide, employing over 500 clinical research professionals exclusively focused on providing professional, high quality study conduct and drug development services. In the past four years, Radiant has conducted more than 8,000 clinical trials across 18 therapeutic specialties.

Contact:
Michael K. Lester Chief Executive Officer RADIANT RESEARCH (425) 468-6200	Pamela M. Spaniac Chief Financial Officer RADIANT RESEARCH (425) 468-6200